Sector News

AstraZeneca spends £23m on gene research tie-up with German biotech

August 23, 2017
Life sciences

AstraZeneca has invested €25m (£23m) into gene messenger drug development, through a research tie-up with German biotech Ethris.

The FTSE 100 drugmaker has agreed to pay Munich-based Ethris the sum upfront, with further payments and royalties possible depending on development progress.

Ethris, which was founded by two German scientists in 2009, specialises in RNA drugs, which instruct human cells to produce therapeutic proteins.

The alliance with AstraZeneca and its biotech division MedImmune will focus on asthma and other respiratory diseases.

Scientists believe the RNA approach holds potential to treat a range of conditions, including cancer and heart disease.

It is not AstraZeneca’s first investment in the field. Last year the company invested a further $140m (£109m) in RNA specialist Moderna Therapeutics, upping its stake to 9pc.

AstraZeneca is looking to bounce back after a negative readout from its lung cancer drugs trial Mystic last month led to its biggest single day share price fall, wiping £10bn from the company’s market value.

By Iain Withers

Source: Telegraph

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend